Premium
Rationale for Combination Antifungal Therapy
Author(s) -
Lewis Russell E.,
Kontoyiannis Dimitrios P.
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.12.149s.34505
Subject(s) - cryptococcal meningitis , antifungal , aspergillosis , cryptococcosis , intensive care medicine , medicine , clinical trial , invasive candidiasis , meningitis , cryptococcus , antifungal drugs , biology , fluconazole , immunology , microbiology and biotechnology , human immunodeficiency virus (hiv) , dermatology , surgery , viral disease
The relentless increase of invasive fungal infections and poor outcomes associated with available antifungal agents prompted the search for better therapeutic strategies. Combining antifungal drugs was recommended as a means to enhance efficacy in a variety of invasive infections including cryptococcosis, candidiasis, and aspergillosis. With the exception of cryptococcal meningitis, data from controlled clinical trials supporting such combinations are sparse. Moreover, little consensus exists regarding which combinations are synergistic or antagonistic in vitro and in vivo. Based on available data, several principles underlie these combinations.